Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Genomics England, Centogene, Cergentis, and More

NEW YORK – Genomics England said this week that it is working with bioinformatics startup Lifebit and Amazon Web Services to create a research platform for research into COVID-19 data and analytics. This effort will include data from Genomics England's research partnership with the Genetics of Mortality in Critical Care (GenOMICC) consortium, the NHS, and Illumina to sequence as many as 20,000 genomes from patients currently or previously in intensive care due to SARS-CoV-2 and up to 15,000 patients who had mild or moderate symptoms.

The platform will later be made available for research on data into Genomics England's 100,000 Genomes Project in pursuit of new insights on cancer and rare diseases, the organization said.


Centogene said this week that it has partnered exclusively with Lufthansa and Fraport, the operator of Frankfurt Airport in Germany, to offer COVID-19 testing to passengers traveling on flights from Frankfurt Airport. Under the terms of the agreement, which also involves medical partner firm Dr. Peter Bauer Laboratoriums, passengers can get tested at a sampling center near the main terminal either the day before or the day of their departures. Tests for passengers arriving at the airport are currently in development. Results are delivered through a digital platform that is connected to the flight ticket.

According to Centogene’s website, the RT-PCR-based test costs €59 ($66) for a version that takes six to eight hours to turn aroundand €139 for an express test with three hours turnaround time. For an additional €9, the company will issue a document verifying the identity of the person who took the test. The partnership is slated to last until July 31, 2021.


Netherlands-based Cergentis said this week that it has received an investment of undisclosed size from venture capital investment fund Novalis Biotech Incubation. The company has been developing target locus amplification technology for cancer diagnostic tests.


Todos Medical announced this week that it’s partnering with Meridian Health Services Network to roll out COVID-19 testing programs across the US. Todos will supplement COVID-19 testing products and services for Meridians network of physical facilities. Meridian completed CLIA validation for Todos Medical’s antibody test. Both PCR and antibody tests will be available through the partnership.


Oncimmune said this week that its Brazilian distributor, Valentech International, obtained marketing authorization in that country for Oncimmune’s EarlyCDT Lung Blood test, an immunodiagnostic test for the early detection of lung cancer. Authorization came from Brazil’s Agência Nacional de Vigilância SanitáriaOncimmune and Valentech signed a distribution deal in 2018 covering Brazil and Colombia.


The Foundation for Innovative New Diagnostics, Molbio Diagnostics, and the Indian Council of Medical Research announced this week that the World Health Organization has endorsed three of their rapid molecular Truenat assays for the initial diagnosis of tuberculosis and subsequent detection of rifampicin resistance in adults and children with signs and symptoms of pulmonary TB. Both Truenat MTB and Truenat MTB Plus detect Mycobacterium tuberculosis bacteria for TB diagnosis, while Truenat MTB-RIF Dx identifies resistance to rifampicin. All three tests are run on the portable, battery-operated PCR-based Truenat device and provide results in less than an hour, the organizations said.


Humana this week announced the start of a pilot home-testing program for COVID-19 using Laboratory Corporation of America's at-home sample collection kits. Humana members who have symptoms consistent with SARS-CoV-2 infection will be able to use the kits to collect nasal swab specimens at home for testing through the Pixel by LabCorp online platform. The self-collection kit received Emergency Use Authorization from the US Food and Drug Administration in April.

Humana also announced a collaboration with WalmartQuest Diagnostics, and PWNHealth to offer plan members drive-thru testing for the coronavirus at select Walmart Neighborhood Market drive-thru pharmacies nationwide.


Enzo Biochem and Farmingdale State College said this week that they are partnering to provide molecular and antibody testing for COVID-19 to the campus community as the college reopens this summer and begins classes in the fall. The collaboration will operate under Enzos School and Institution Testing (SIT) Program to provide several pre-scheduled testing clinics onsite each month at the college. Campus member who needs to be tested immediately will be prioritized at Enzo’s clinical lab in Farmingdale. Testing will be conducted using Enzo's AmpiProbe SARS-CoV-2 swab test and serological antibody (IgG) blood testThe company also plans to make additional testing, including expanded antibody (IgM, IgA) testing, available in the near term.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

 

 

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.